| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 451,0 k € | -2.3% | 461,5 k € | +16.2% | 397,1 k € | -9.7% | 439,8 k € | +46.1% | 300,9 k € | +7.9% | 278,9 k € | -13.8% | 323,5 k € | -0.1% | 323,8 k € | +18.7% | 272,8 k € | -13.5% | 315,2 k € | +3.4% | 304,7 k € | -7.4% | 329,2 k € | +12.7% | 292,2 k € | +20.7% | 242,0 k € | +23.9% | 195,2 k € | +1.2% | 192,9 k € | +1.8% | 189,4 k € | +2.7% | 184,4 k € | +10.8% | 166,4 k € | |
| EBITDA | 416,6 k € | -0.6% | 419,1 k € | +16.5% | 359,6 k € | -12.5% | 410,9 k € | +48.8% | 276,1 k € | +8.1% | 255,4 k € | -17.2% | 308,4 k € | -1.7% | 313,8 k € | +20.6% | 260,1 k € | -14.1% | 302,9 k € | +4.2% | 290,7 k € | -7.7% | 315,1 k € | +12.5% | 280,0 k € | +20.4% | 232,6 k € | +24.7% | 186,5 k € | +1.9% | 183,1 k € | +2.1% | 179,4 k € | +2.5% | 175,0 k € | +11.4% | 157,0 k € | |
| Operating profit | 373,6 k € | +34.0% | 278,8 k € | -10.2% | 310,3 k € | -8.2% | 338,2 k € | +54.3% | 219,2 k € | +11.1% | 197,3 k € | -21.1% | 250,0 k € | -5.5% | 264,6 k € | +33.3% | 198,6 k € | -18.1% | 242,6 k € | +10.9% | 218,8 k € | -10.3% | 244,1 k € | +82.6% | 133,6 k € | +9.2% | 122,4 k € | +2.6% | 119,3 k € | -7.0% | 128,3 k € | -7.1% | 138,2 k € | +7.3% | 128,8 k € | +16.0% | 111,0 k € | |
| Profit/loss | 279,1 k € | +43.6% | 194,4 k € | -13.0% | 223,4 k € | -2.7% | 229,7 k € | +48.5% | 154,6 k € | +18.4% | 130,6 k € | -21.3% | 165,9 k € | +4.4% | 158,9 k € | +48.9% | 106,7 k € | -23.5% | 139,5 k € | +4.8% | 133,1 k € | -16.7% | 159,7 k € | +95.6% | 81,6 k € | +0.5% | 81,2 k € | -4.3% | 84,8 k € | -5.3% | 89,5 k € | -2.6% | 91,9 k € | +7.6% | 85,4 k € | +16.7% | 73,2 k € | |
| Equity | 2,2 M € | +14.6% | 1,9 M € | +11.3% | 1,7 M € | +14.9% | 1,5 M € | +18.1% | 1,3 M € | +13.9% | 1,1 M € | +13.3% | 981,4 k € | +20.3% | 815,5 k € | -29.5% | 1,2 M € | +10.2% | 1,0 M € | +15.3% | 910,4 k € | +17.1% | 777,3 k € | +15.5% | 673,2 k € | +13.8% | 591,6 k € | +15.9% | 510,4 k € | +19.9% | 425,6 k € | +26.6% | 336,1 k € | +37.7% | 244,1 k € | +0.2% | 243,7 k € | |
| Total assets | 2,3 M € | +20.4% | 1,9 M € | +5.2% | 1,8 M € | +12.9% | 1,6 M € | +14.5% | 1,4 M € | +14.9% | 1,2 M € | +5.5% | 1,2 M € | -24.8% | 1,6 M € | +5.7% | 1,5 M € | +5.1% | 1,4 M € | +6.0% | 1,3 M € | +5.9% | 1,3 M € | +3.9% | 1,2 M € | +13.8% | 1,1 M € | +55.6% | 680,1 k € | +5.4% | 645,5 k € | +46.0% | 442,1 k € | -2.7% | 454,6 k € | +14.2% | 398,2 k € | |
| Cash | 400,0 k € | -20.6% | 503,5 k € | -41.8% | 865,2 k € | +38.6% | 624,3 k € | +1.3% | 616,1 k € | +39.0% | 443,2 k € | +73.0% | 256,2 k € | -69.8% | 848,1 k € | +17.6% | 720,9 k € | +23.5% | 583,6 k € | +35.6% | 430,3 k € | +35.3% | 318,0 k € | +45.0% | 219,3 k € | +25.2% | 175,1 k € | +55.4% | 112,7 k € | +140.6% | 46,8 k € | +381.7% | 9,7 k € | -89.3% | 91,1 k € | +88.9% | 48,2 k € | |
| Debts | 136,1 k € | +567.2% | 20,4 k € | -82.8% | 118,6 k € | -8.8% | 130,1 k € | -15.5% | 154,0 k € | +24.3% | 123,8 k € | -35.1% | 190,8 k € | -74.4% | 745,2 k € | +142.0% | 307,9 k € | -13.2% | 354,8 k € | -14.4% | 414,7 k € | -12.5% | 473,6 k € | -10.7% | 530,3 k € | +14.2% | 464,5 k € | +173.8% | 169,7 k € | -22.8% | 219,9 k € | +107.9% | 105,8 k € | -49.7% | 210,4 k € | +36.3% | 154,4 k € | |
| Staff | — | — | — | — | — | — | — | — | — | 0,4 | 0,4 | 0,5 | 0,4 | 0,3 | 0,3 | 0,3 | 0,3 | 0,3 | 0,4 | |||||||||||||||||||
Private limited company · Ieper · incorporated on 16/12/2002
Private limited company profitable and well capitalised. Cash position declining (-20.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
DR. JOHAN VANDEN BROUCKE is a Private limited company incorporated in 2002. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Ieper.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette